Vectorized antibodies hold promise to overcome many of these limitations and provide a great opportunity for DNA and RNA technology companies to enter larger markets compared with the rare disease ...
Vectorized Inc., a new data management startup, today disclosed that it has raised $15.5 million across two funding rounds from Lightspeed Venture Partners and Alphabet Inc.’s GV fund. The startup’s ...
AMSTERDAM & BOSTON & SEATTLE, September 18, 2025--(BUSINESS WIRE)--VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of ...
ORLANDO, Fla.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that ...
PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology ...
A randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. This is an ASCO Meeting Abstract from the 2012 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results